94 related articles for article (PubMed ID: 19729953)
1. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2009; 52(6):301-9. PubMed ID: 19729953
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
[TBL] [Abstract][Full Text] [Related]
4. Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.
Hu Z; Liu Y; Qiu L; Fan Z; Nie W; Liang S; Jin R
Virol J; 2015 Dec; 12():220. PubMed ID: 26684004
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
6. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Matsuda M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Intervirology; 2005; 48(6):372-80. PubMed ID: 16024941
[TBL] [Abstract][Full Text] [Related]
7. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188
[TBL] [Abstract][Full Text] [Related]
8. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407
[TBL] [Abstract][Full Text] [Related]
9. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
[TBL] [Abstract][Full Text] [Related]
10. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
[TBL] [Abstract][Full Text] [Related]
11. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
12. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
13. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
14. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Fukuda K; Mita E; Haruna Y; Inoue A; Imai Y; Hosui A; Miyagi T; Yoshida Y; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Med Virol; 2011 Mar; 83(3):419-27. PubMed ID: 21264862
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Miyakawa Y; Kumada H
Intervirology; 2007; 50(5):361-8. PubMed ID: 17728547
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
[TBL] [Abstract][Full Text] [Related]
17. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy.
Kitamura S; Tsuge M; Hatakeyama T; Abe H; Imamura M; Mori N; Saneto H; Kawaoka T; Mitsui F; Hiraga N; Takaki S; Kawakami Y; Aikata H; Takahashi S; Ohishi W; Ochi H; Hayes CN; Chayama K
Antivir Ther; 2010; 15(8):1087-97. PubMed ID: 21149915
[TBL] [Abstract][Full Text] [Related]
18. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
19. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
20. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
